A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Romaco at INTERPHEX 2023 – Broad Portfolio for Lab Applications

Romaco’s technologies and services for laboratory applications will be at the center of the one stop solutions provider’s trade fair exhibit. The multipurpose VENTILUS® Lab fluid bed processor from Romaco Innojet and the KTP 1X R&D tablet press from Romaco Kilian will be on display at the upcoming even

Romaco will take advantage of INTERPHEX to show technologies and services for laboratory applications. The one stop solutions provider’s processing portfolio includes high shear mixers, fluid bed processors, tablet presses and tablet coaters for laboratory scale production. Sustainable system design is a key development priority with all Romaco machines – for example, through targeted energy savings in processing or reduced raw material consumption in the manufacture and processing of pharmaceutical powders, granulates and tablets. These measures not only improve the carbon footprint; they also go hand in hand with lower production costs.

Romaco additionally has six laboratories for granulation, tableting and film coating as well as filling and packing of pharmaceutical solids and liquids. These knowledge centers serve as the first port of call for expert advice, product analyses, process optimization and machine training. Parallel to this, lab specialists from Innojet, Kilian and Tecpharm provide scale-up and product development support to users in the pharmaceutical industry.

VENTILUS® Lab fluid bed processor from Romaco Innojet – a multipurpose all-rounder with significant energy saving potential

Designed for laboratory-scale applications, the VENTILUS® Lab fluid bed processor from Romaco Innojet is used for granulating, drying and coating particle sizes from 10 μm to 2 mm. This multipurpose lab unit produces batches from 0.7 to 7.0 liters in size. Due to the enhanced processing efficiency inside the cylindrical product container, the VENTILUS® Lab allows up to 25 percent shorter batch processing times and hence much lower power consumption. The process air is introduced through the ORBITER® booster plate, which ensures homogeneous flow conditions and extremely gentle intermixing of the materials. In combination with the ROTOJET®, the central bottom spray nozzle, the ORBITER® booster forms a unique functional unit enabling simple scale-up. Thanks to the innovative fluid bed components invented by Dr. h. c. Herbert Hüttlin, the product movement inside the process container can be accurately controlled. The spray liquid is consequently applied very precisely, so that formulations achieving the modified release profile are possible using 10 to 15 percent less material. The targeted reduction in spray liquid and power consumption means the VENTILUS® Lab also results in substantially fewer carbon dioxide emissions from fluid bed processes. Furthermore, the rotating SEPAJET® filter system minimizes product loss by preventing any particles retained by the filter from being discharged from the process.

KTP 1X R&D tablet press 2.0 from Romaco Kilian – access to research data worldwide at any time – Industry 4.0 ready

The KTP 1X is the newest generation of Romaco Kilian’s R&D tablet presses for laboratory use. This single-stroke press was designed as an all-in-one instrument for research and development activities and is suitable for pressing mono-layer, bi-layer and triple-layer tablets as well as tab-in-tab formats. It achieves compression forces of up to 80 kN depending on the model and a maximum output of 1800 tablets per hour. This versatile R&D press enables the various tableting parameters, such as compression force or the possible tableting speed, to be automatically determined. The smart measurement system evaluates huge amounts of data in next to no time for this purpose. The KTP 1X is moreover capable of simulating any standard rotary press, making it much easier to conduct scale-up trials. In addition to the production of clinical samples, the technology allows detailed troubleshooting and hence supports process optimization. Thanks to the machine’s extremely good rigidity, the punch position in particular can be measured more precisely now. This high measuring accuracy goes hand in hand with extremely low product consumption – so that the KTP 1X is not only very accurate but also cost-efficient and sustainable. Only a few test series are required to obtain meaningful results, because compression studies are highly automated. With its very small compaction area, the tablet press has a small footprint and is quick and easy to clean – for even bigger time and energy savings. What’s more, the machine ships with a data module that gives users access to raw measurement data worldwide at any time, even when the machine is not in operation.

On show at INTERPHEX in New York (USA) from April 25 to 27, 2023 (Javits Center, Stand 3309).

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy